Liquidia (LQDA) vs Prestige Consumer Healthcare (PBH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Liquidia (LQDA) has outperformed Prestige Consumer Healthcare (PBH) over the past year, gaining 12.9% versus a loss of 23.2%. Over five years, LQDA leads with a +755.6% price change compared with -17.4% for PBH. Liquidia is the larger company by market cap ($2.45 billion vs $2.28 billion), about 1.1 times the size.
On valuation, Prestige Consumer Healthcare trades at a lower forward P/E (9.5x vs 11.8x for Liquidia). Prestige Consumer Healthcare converts more of its revenue into profit, with a net margin of 17.5% versus -43.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LQDA | PBH |
|---|---|---|
| Share price | $27.38 | $48.23 |
| Market cap | $2.45B | $2.28B |
| 1-day change | -2.28% | +0.75% |
| YTD return | -20.61% | -21.82% |
| 1-year return | +12.91% | -23.19% |
| 5-year return | +755.63% | -17.44% |
| P/E ratio (TTM) | 19.70 | 13.51 |
| Forward P/E | 11.81 | 9.49 |
| EPS (TTM) | $1.39 | $3.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $158.32M | $1.09B |
| Revenue growth (YoY) | +1031.18% | -4.31% |
| Net income (latest FY) | $-68.92M | $190.30M |
| Gross margin | — | 54.71% |
| Operating margin | -32.45% | 28.42% |
| Net margin | -43.53% | 17.48% |
| 52-week high | $93.61 | $71.07 |
| 52-week low | $21.94 | $42.62 |
| Distance from 52-week high | -70.75% | -32.14% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +81.41% | +40.58% |
| Average volume | 2.50M | 546.95K |
| Shares outstanding | 89.51M | 47.37M |
| Employees | 216 | 890 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LQDA has outperformed PBH by 36.1 percentage points over the past year.
- Liquidia trades at a higher earnings multiple (19.7x vs 13.5x trailing P/E).
- Prestige Consumer Healthcare is more profitable, keeping 17.5 cents of every revenue dollar as net income versus -43.5 cents for Liquidia.
- Liquidia grew revenue faster in its latest fiscal year (+1031.18% vs -4.31%).
About Liquidia
LQDA stock →Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
About Prestige Consumer Healthcare
PBH stock →Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Health Care · Biotechnology: Pharmaceutical Preparations · 890 employees
LQDA vs PBH FAQ
Which is bigger, Liquidia or Prestige Consumer Healthcare?
Liquidia (LQDA) is larger, with a market capitalization of $2.45B compared with $2.28B for Prestige Consumer Healthcare (PBH).
Which stock has performed better over the past year, LQDA or PBH?
LQDA returned +12.91% over the past 12 months, compared with -23.19% for PBH (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, LQDA or PBH?
PBH has the lower trailing P/E at 13.5, versus 19.7 for LQDA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Liquidia and Prestige Consumer Healthcare in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.